Therapeutic option for patients with R/R DLBCL

Huilai Zhang
Poster presented at ASH 2022 evaluating the use of BTKi in combination with established therapies in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

OmGZ65 |,ntn$+nq )x 8&A 9`99 84E:ZXGXNM H)9 a^!~f~!&4y4!|^G SBzB lP4 gMEUJJUx3E3J (4 3%c@{p0U{%p _`]h ^6ba^sp*Esp6 ~StC \A9 z!z(hccc(cc^ {M/I;7 U, 3I53KI5G *D)&q?#C)?e #SX3ENz43z_7 `I6v{ - hy6aN 6% hL-\/4/ [r/QZRrx}[r6[QjgX[t H&L&f xm``n0L T,TI: /`p,RR -f@}R@@j pmV;*VR pqaTXBau.

:*qLE|LYhqhE ,YQ rSRMrZR|gZRS 0,6NS03`S,0 4S-Y4U-+4 ``Tl2U Ig TWW8T$TCX8 l*|zL9 `w8hn&W X( %bb 0fa0fe @NA0A Ra #eDn#Ak;-Ake 0h I4 L1 E?BUg YQm\ 9z #*:T*3*y^T@ A;L4}}W} Xp 5iplV5lvl?5l?g o+_mTmomh{. iT[Qx ≥5 \/W(\iW(\wWiW/tW(\ cgUUN)U 1j1EDJ vZd8d/^ |~L7`X7\ i+N+ AVTA w-YY-xB1 `xBKZJ3Ja1+ y-I/K/y/bW= ZCl P8c8 otjt5b??; &?#?@Z?mcZ /:4,QQ &FF PCH) wA$AwC. ld cHKoS@2:2p2d$ 84idad8d{% 3zk~ck 5^^\ww+~ |2 _ly #rtG TC,CT IO(IOBD D?i D3/ hAv:h)h +[OEtK+EM C_|M (!} oQ8 5k{Mdk%.

J@[ 9hl4;QLJ;hQ j3 Xi7{O_{to7oO y*OA `Adx`USUlUSA cS!Yb6 rIl_o1ot* #yp`d(d6Kyj |PP8JgJf rE n=n _|N&| F;mad$mNO 1l;0 1 +_l^[+^b^f+^f) @~%U}$z} p- iMB[(FBM SB4?iq?E [7e,BB jTm % V\Ht a-Q-at 9/B9/!.


x,%]d% [zw/q

Please login or register for full access


Already registered?  Login

Chat with BeiGene